At Ichnos Sciences, we’re working to make real progress in science and medicine. Explore our recent publications to discover how we’re shifting medicine forward.
|05/03/2021||ISB 830||Telazorlimab in Atopic Dermatitis: Phase 2b Study Shows Improvement at 16 Weeks||Sher, L.||2021 Society for Investigative Dermatology Virtual Meeting|
|02/06/2019||ISB 830||GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis||Guttman-Yassky E. et al.||Journal of Allergy and Clinical Immunology|
Note: Assets that were previously identified as GBR XXXX are now identified as ISB XXXX.